ACE Inhibitors Versus ARBs Versus DRIs: A Systematic Update
نویسندگان
چکیده
منابع مشابه
RAAS inhibition: ACE inhibitors and ARBs
Survivors of myocardial infarction (MI) are at high risk of disability and death. This is due to infarct-related complications such as heart failure, cardiac remodeling with progressive ventricular dilation, dysfunction, and hypertrophy, and arrhythmias including ventricular and atrial fibrillation. Angiotensin (Ang) II, the major effector molecule of the renin–angiotensin–aldosterone system (R...
متن کاملThe ACE of ARBs?
In 2002, my colleagues and I 1 suggested that blockade of the renin–angiotensin system may prevent diabetes by promoting adipogenesis, thereby allowing redistribution of fat from dangerous visceral and ectopic fat deposits to less-dangerous subcutaneous depots. This hypothesis was based on our observation that angiotensin II inhibits human preadipocyte differentiation.2 We subsequently demonstr...
متن کاملTelmisartan: the ACE of ARBs?
In 2002, my colleagues and I 1 suggested that blockade of the renin–angiotensin system may prevent diabetes by promoting adipogenesis, thereby allowing redistribution of fat from dangerous visceral and ectopic fat deposits to less-dangerous subcutaneous depots. This hypothesis was based on our observation that angiotensin II inhibits human preadipocyte differentiation.2 We subsequently demonstr...
متن کاملLowered cancer risk with ACE inhibitors/ARBs: a population-based cohort study.
There are conflicting reports on cancer risk associated with angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs). This retrospective cohort study was conducted to analyze the risk of cancer development in patients who received ACE inhibitors/ARBs as treatment for essential hypertension. Using the Taiwan National Health Insurance Research Database, 297,688 eligibl...
متن کاملAdding ACE inhibitors or ARBs to standard therapy for stable ischemic heart disease.
Evidence-Based Answer Adding an ACE inhibitor to standard therapy reduces total mortality and cardiovascular events. Adding an ARB also reduces cardiovascular events. Overall effects are modest. Current evidence does not support the use of ACE inhibitor and ARB combinations over ACE inhibitors alone, because the risk of adverse events increases without additional benefit. Evidence suggests that...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of General Internal Medicine
سال: 2012
ISSN: 0884-8734,1525-1497
DOI: 10.1007/s11606-012-2213-3